A Selective Nuclear Factor-κB Inhibitor, JSH-23, Exhibits Antidepressant-like Effects and Reduces Brain Inflammation in Rats

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2024 Oct 26

PMID 39458912

Authors

Ahmad Nassar

Jacob Kaplanski

Abed N Azab

Affiliations

Soon will be listed here.

Abstract

Background: Accumulating evidence suggests that nuclear factor (NF)-κB is involved in the pathophysiology of mood disorders.

Objectives And Methods: We conducted two experimental protocols in rats to investigate the effects of a selective NF-κB inhibitor (JSH-23) on (i) lipopolysaccharide (LPS)-induced inflammation and (ii) on behavioral phenotypes in rat models of depression (sucrose consumption test and forced swim test) and mania (amphetamine-induced hyperactivity test). Additionally, we tested the effects of JSH-23 on levels of inflammatory components (interleukin-6, prostaglandin E2, nuclear phospho-p65, and tumor necrosis factor-α) in the brain.

Results: Acute treatment with JSH-23 (10 mg/kg, intraperitoneally [ip]) led to potent anti-inflammatory effects in LPS-treated rats, including a diminished hypothermic response to LPS and a reduction in pro-inflammatory mediators' levels in the brain. Chronic treatment with JSH-23 (3 mg/kg, ip, once daily, for 14 days) resulted in robust antidepressant-like effects (increased sucrose consumption and decreased immobility time). The antidepressant-like effects of JSH-23 were mostly accompanied by a reduction in levels of pro-inflammatory mediators in the brain. On the other hand, JSH-23 did not reduce amphetamine-induced hyperactivity.

Conclusions: Altogether, these data suggest that NF-κB may be a potential therapeutic target for pharmacological interventions for depression.

References

Karin M, Yamamoto Y, Wang Q . The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov. 2004; 3(1):17-26. DOI: 10.1038/nrd1279. View

Shih R, Wang C, Yang C . NF-kappaB Signaling Pathways in Neurological Inflammation: A Mini Review. Front Mol Neurosci. 2016; 8:77. PMC: 4683208. DOI: 10.3389/fnmol.2015.00077. View

Modabbernia A, Taslimi S, Brietzke E, Ashrafi M . Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol Psychiatry. 2013; 74(1):15-25. DOI: 10.1016/j.biopsych.2013.01.007. View

Ditzen C, Tang N, Jastorff A, Teplytska L, Yassouridis A, Maccarrone G . Cerebrospinal fluid biomarkers for major depression confirm relevance of associated pathophysiology. Neuropsychopharmacology. 2011; 37(4):1013-25. PMC: 3280652. DOI: 10.1038/npp.2011.285. View

Scaini G, Mason B, Diaz A, Jha M, Soares J, Trivedi M . Dysregulation of mitochondrial dynamics, mitophagy and apoptosis in major depressive disorder: Does inflammation play a role?. Mol Psychiatry. 2021; 27(2):1095-1102. DOI: 10.1038/s41380-021-01312-w. View

Sun Y, Zhang L, Johnston N, Torrey E, Yolken R . Serial analysis of gene expression in the frontal cortex of patients with bipolar disorder. Br J Psychiatry Suppl. 2001; 41:s137-41. DOI: 10.1192/bjp.178.41.s137. View

Ling J, Kumar R . Crosstalk between NFkB and glucocorticoid signaling: a potential target of breast cancer therapy. Cancer Lett. 2012; 322(2):119-26. DOI: 10.1016/j.canlet.2012.02.033. View

Martin-Hernandez D, Caso J, Meana J, Callado L, Madrigal J, Garcia-Bueno B . Intracellular inflammatory and antioxidant pathways in postmortem frontal cortex of subjects with major depression: effect of antidepressants. J Neuroinflammation. 2018; 15(1):251. PMC: 6122627. DOI: 10.1186/s12974-018-1294-2. View

Shvartsur R, Agam G, Shnaider A, Uzzan S, Nassar A, Jabarin A . Safety and Efficacy of Combined Low-Dose Lithium and Low-Dose Aspirin: A Pharmacological and Behavioral Proof-of-Concept Study in Rats. Pharmaceutics. 2021; 13(11). PMC: 8619680. DOI: 10.3390/pharmaceutics13111827. View

10.

Nassar A, Sharon-Granit Y, Azab A . Psychotropic drugs attenuate lipopolysaccharide-induced hypothermia by altering hypothalamic levels of inflammatory mediators in rats. Neurosci Lett. 2016; 626:59-67. DOI: 10.1016/j.neulet.2016.05.019. View

11.

Freitas R, Fraga C . NF-κB-IKKβ Pathway as a Target for Drug Development: Realities, Challenges and Perspectives. Curr Drug Targets. 2018; 19(16):1933-1942. DOI: 10.2174/1389450119666180219120534. View

12.

Nassar A, Azab A . Effects of lithium on inflammation. ACS Chem Neurosci. 2014; 5(6):451-8. PMC: 4063502. DOI: 10.1021/cn500038f. View

13.

Rayet B, Gelinas C . Aberrant rel/nfkb genes and activity in human cancer. Oncogene. 1999; 18(49):6938-47. DOI: 10.1038/sj.onc.1203221. View

14.

Guardado P, Olivera A, Rusch H, Roy M, Martin C, Lejbman N . Altered gene expression of the innate immune, neuroendocrine, and nuclear factor-kappa B (NF-κB) systems is associated with posttraumatic stress disorder in military personnel. J Anxiety Disord. 2016; 38:9-20. DOI: 10.1016/j.janxdis.2015.12.004. View

15.

Rubin E, Pippione A, Boyko M, Einaudi G, Sainas S, Collino M . A New NF-κB Inhibitor, MEDS-23, Reduces the Severity of Adverse Post-Ischemic Stroke Outcomes in Rats. Brain Sci. 2022; 12(1). PMC: 8773493. DOI: 10.3390/brainsci12010035. View

16.

Nadjar A, Tridon V, May M, Ghosh S, Dantzer R, Amedee T . NFkappaB activates in vivo the synthesis of inducible Cox-2 in the brain. J Cereb Blood Flow Metab. 2005; 25(8):1047-59. DOI: 10.1038/sj.jcbfm.9600106. View

17.

Wang A, Miller B . Meta-analysis of Cerebrospinal Fluid Cytokine and Tryptophan Catabolite Alterations in Psychiatric Patients: Comparisons Between Schizophrenia, Bipolar Disorder, and Depression. Schizophr Bull. 2017; 44(1):75-83. PMC: 5768046. DOI: 10.1093/schbul/sbx035. View

18.

Roussos P, Katsel P, Davis K, Giakoumaki S, Lencz T, Malhotra A . Convergent findings for abnormalities of the NF-κB signaling pathway in schizophrenia. Neuropsychopharmacology. 2012; 38(3):533-9. PMC: 3547205. DOI: 10.1038/npp.2012.215. View

19.

Volk D, Moroco A, Roman K, Edelson J, Lewis D . The Role of the Nuclear Factor-κB Transcriptional Complex in Cortical Immune Activation in Schizophrenia. Biol Psychiatry. 2018; 85(1):25-34. PMC: 6289758. DOI: 10.1016/j.biopsych.2018.06.015. View

20.

Wei J, Lu Y, Li K, Goodman M, Xu H . The associations of late-life depression with all-cause and cardiovascular mortality: The NHANES 2005-2014. J Affect Disord. 2021; 300:189-194. DOI: 10.1016/j.jad.2021.12.104. View